Daiwa: Raised the Target Price for SINO BIOPHARM to 4 Hong Kong dollars and reiterated the "Buy" rating.

Daiwa released a research report stating that SINO BIOPHARM (01177) was driven by Innovative Drugs last year, with an income growth of 10.2% year-on-year; gross margin increased by 0.5 percentage points compared to the previous year; the ratio of sales and administrative expenses remained stable at 42.1%; the research and development ratio rose by 0.8 percentage points; adjusted net income increased by 33.5%. The firm raised its revenue forecast for SINO BIOPHARM for the next fiscal year by 9% to 12%, reiterating its 'Buy' rating, with the Target Price increased from HKD 3.5 to HKD 4. The firm also raised the group's Innovative Drugs revenue forecast for the next two years by 4% and 15%, respectively, to 15 billion and 19 billion RMB.

Sina Hong Kong stocks26minutes ago

AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."

① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.

cls.cnApr 11 07:59 ET

Sino Biopharmaceutical Gets China Nod for Hematologic Tumor Drug Trial

MT NewswiresApr 10 05:56 ET

SINO BIOPHARM (01177.HK) "TQB3019 (BTKPROTAC)" clinical trial application has been approved by NMPA.

On April 9, Gelonghui reported that SINO BIOPHARM (01177.HK) announced that its independently developed "TQB3019 (BTK PROTAC)" has received clinical trial approval from the National Medical Products Administration of China (NMPA) for the treatment of hematologic tumors. TQB3019 is an oral, targeted BTK protein degradation targeting chimeric (PROTAC) drug developed based on the group's OAPD technology platform. As a bifunctional molecule, TQB3019 initiates the ubiquitin-proteasome pathway by binding to BTK protein and E3 ubiquitin ligase, which degrades the target protein.

Gelonghui FinanceApr 9 06:17 ET

Express News | Sino Biopharmaceutical - Tqb3019 (Btk Protac) Approved for Clinical Trial by Nmpa

ReutersApr 9 06:14 ET

What is the impact on the domestic Pharmaceutical industry? Many listed companies respond to the USA's tariff on Pharmaceutical.

① Most surveyed listed Pharmaceutical companies are not panicking. Some companies state that if Pharmaceutical tariffs are implemented, they will raise prices to ensure product gross margin; ② Other companies mention that their products are difficult to substitute in the U.S. and are closely monitoring related developments; ③ Industry experts state that if Pharmaceutical tariffs are implemented, compared to Active Pharmaceutical Ingredients and generic drugs, Innovative Drugs may be the least impacted.

cls.cnApr 9 05:24 ET